{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-004663","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2023-04-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.799493+00:00","generated_at":"2026-06-17T02:49:37.352915+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tenax prioritizes oral levosimendan Phase 3 for PH-HFpEF in 2023","bullets":["Company to initiate Phase 3 trial of TNX-103 (oral levosimendan) for PH-HFpEF in 2023.","PH-HFpEF affects >1.6M North Americans; no FDA-approved therapy exists.","Patent estate expanded; protection through at least 2040 with additional IP expected in 2023.","FDA agreed Phase 3 endpoints: 6-minute walk distance at 12 weeks or clinical worsening at 24 weeks.","Imatinib Phase 3 deferred beyond 2023 pending fundraising and strategic review."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-004663","json":"https://secwatch.observer/filing/0001654954-23-004663.json","markdown":"https://secwatch.observer/filing/0001654954-23-004663.md","text":"https://secwatch.observer/filing/0001654954-23-004663.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000165495423004663/0001654954-23-004663-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000165495423004663/tenx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T02:49:37.352915+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}